{"entity":{"id":"mirxes","kind":"company","name":"Mirxes","aka":[],"tldr":"A Singapore microRNA diagnostics company with a stomach cancer blood test and a multi-cancer test in development.","summary":"Mirxes sells GASTROClear, a microRNA blood test for gastric cancer that it reports holds FDA Breakthrough Device designation (August 2023) and NMPA approval (October 2025). Its multi-cancer screening test is in development through Project CADENCE (NCT05633342), launched in July 2022 for up to nine cancers using microRNA and DNA methylation; no multi-cancer results were found.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://mirxes.com/"},{"label":"ClinicalTrials.gov NCT05633342","url":"https://clinicaltrials.gov/study/NCT05633342"}],"tags":[],"related":[],"cancers":["gastric"],"sections":["early-detection","diagnostics"],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["cadence-mirxes"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Singapore","country":"SG","companyType":"diagnostics","website":"https://mirxes.com/","investors":[],"funding":[]},"route":"/companies/mirxes/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"trial":[{"id":"cadence-mirxes","kind":"trial","name":"Project CADENCE (Mirxes multi-cancer blood test)","route":"/trials/cadence-mirxes/"}]}}